Vertex Pharmaceuticals (VRTX) Earnings Date & Reports
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases... Show more
VRTX is expected to report earnings to rise 5.59% to $4.72 per share on July 30
Vertex Pharmaceuticals (VRTX) First Quarter 2026 Earnings Recap: Solid CF Growth Offsets Non-CF Ramp Challenges
Key Takeaways
- Vertex reported Q1 2026 total revenue of $2.99 billion, up 8% year-over-year from $2.77 billion, driven by cystic fibrosis (CF) franchise strength.
- Non-GAAP diluted EPS (earnings per share) came in at $4.47, surpassing consensus estimates around $4.23-$4.43; GAAP EPS was $4.02.
- CF products generated $2.92 billion, with TRIKAFTA/KAFTRIO at $2.35 billion and new entrant ALYFTREK at $424 million.
- Non-CF products CASGEVY and JOURNAVX contributed $72 million combined, accounting for over 25% of revenue growth.
- Company reiterated full-year 2026 revenue guidance of $12.95-$13.1 billion, including at least $500 million from non-CF products.
- Cash position stood at $13.0 billion, supporting ongoing share repurchases and pipeline investments.
Earnings Context and Why It Matters
Vertex Pharmaceuticals (VRTX), a leader in cystic fibrosis treatments, released its first quarter 2026 results on May 4, 2026, for the period ended March 31, 2026. This report is pivotal as investors assess the balance between mature CF franchise growth and the ramp-up of newer therapies in sickle cell disease, beta thalassemia, and acute pain. Amid biotech sector pressures from pricing concerns and pipeline risks, Vertex's execution on diversification is key. Strong CF demand and early non-CF contributions underscore resilience, while guidance reaffirmation signals confidence in hitting annual targets despite macro headwinds like potential tariffs.
Vertex delivered total revenues of $2.99 billion for Q1 2026, an 8% increase from $2.77 billion in Q1 2025, slightly below some consensus expectations near $3.0 billion but aligned with Zacks estimates. U.S. revenues rose 7% to $1.78 billion, while ex-U.S. grew 9% to $1.21 billion, bolstered by CF uptake and foreign exchange benefits.
The CF portfolio drove results with $2.92 billion in sales: TRIKAFTA/KAFTRIO at $2.35 billion, ALYFTREK at $424 million (cumulative over $1 billion since launch), and other CF products at $136 million. Newer launches shone with CASGEVY (for sickle cell disease and transfusion-dependent beta thalassemia, or TDT) at $43 million and JOURNAVX (acute pain) at $29 million, together fueling more than 25% of growth.
Non-GAAP diluted EPS reached $4.47, beating Zacks consensus of $4.23 by 5.76% and prior-year $4.06; GAAP EPS was $4.02 versus $2.49 last year. Non-GAAP operating margin hit 44%. Vertex reiterated 2026 guidance: total revenue $12.95-$13.1 billion; non-GAAP R&D (research and development), acquired IPR&D (in-process research and development), and SG&A (selling, general, and administrative) expenses $5.65-$5.75 billion; non-GAAP tax rate 19.5%-20.5%.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your stock analysis workflow.
Market Reaction and Investor Sentiment
Post-earnings, VRTX shares showed mixed signals: closing up 1.40% at $429.85 on May 4 amid after-hours fluctuations, with some reports noting a slight 0.1% aftermarket gain to $424.02 and others a 1.14% dip.+Stock+Falls+on+Q1+2026+Earnings) The EPS beat was overshadowed by revenue coming in line or marginally soft versus higher expectations, tempering enthusiasm. Sentiment remains positive on CF reliability and pipeline momentum, though investors parsed conservative non-CF ramp commentary. Analyst consensus holds overweight with targets around $548, reflecting long-term confidence.
Forward Outlook and Key Factors to Monitor
Vertex's reiterated 2026 guidance points to steady execution, with CF therapies like ALYFTREK and TRIKAFTA now eligible for ~95% of U.S. CF patients following label expansions. Investors should watch regulatory submissions for pediatric indications (ages 2-5 for ALYFTREK, 1-<2 for TRIKAFTA) planned for H1 2026.
Non-CF momentum is critical: CASGEVY's U.S. filing for ages 5-<12 (priority review) and Germany pricing deal could accelerate adoption; JOURNAVX targets 3x prescription growth with new Medicare and Medicaid coverage adding millions of lives. Cumulative metrics—over 500 CASGEVY initiations and 1 million JOURNAVX prescriptions—signal scaling potential.
Pipeline catalysts loom large. Povetacicept's BLA (biologics license application) for IgA nephropathy (IgAN) seeks accelerated approval post-positive Phase 3 data; Phase 3 in primary membranous nephropathy advances. CF next-gen VX-828 dosing completes H1 2026, readout H2; pain programs like suzetrigine enrollment ends year-end. Inaxaplin Phase 3 interim eyes early 2027.
Balance sheet strength ($13 billion cash) funds R&D (~$100 million acquired IPR&D) and repurchases amid immaterial tariff impacts. Track CF pricing/demand, non-CF uptake, and regulatory wins for diversification progress.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a company that discovers and develops novel, small molecule pharmaceuticals
Industry Biotechnology